Tirzepatide Cardiovascular Outcomes: The SURMOUNT-MMO Trial Explained

Tirzepatide (Mounjaro), Eli Lilly's dual GIP/GLP-1 receptor agonist, has been under investigation in the SURMOUNT-MMO (morbidity and mortality in obesity) trial, a large-scale outcomes study enrolling over 15,000 adults with overweight or obesity and without diabetes, who have either established cardiovascular disease or multiple cardiovascular risk factors ^[1].

Study Design

SURMOUNT-MMO (NCT05556512) is a randomised, double-blind, placebo-controlled, event-driven trial. Participants were randomised to Tirzepatide, escalated to the maximum tolerated dose, or placebo. The primary endpoint is a five-component composite: death from any cause, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, or heart failure events ^[1]. The trial registry lists follow-up of up to five years and an estimated primary completion date of October 2027.

Context: Why This Trial Matters

Semaglutide's SELECT trial (published in NEJM, November 2023) demonstrated a 20% relative risk reduction in MACE with Semaglutide in patients with established cardiovascular disease and overweight or obesity but without diabetes ^[2]. The question facing the research community is whether dual agonism, specifically the addition of GIP receptor activation, provides incremental cardiovascular benefit beyond GLP-1 alone.

Preclinical data suggest GIP receptor activation may confer direct cardiometabolic effects through:

• Reduction of atherosclerotic plaque inflammation, seen when GIP was raised in ApoE knockout mice ^[3]
• Improved insulin sensitivity that is partly independent of body-weight reduction, seen with GIP receptor agonism in obese mice ^[4]

These findings are not fully consistent across studies, and a 2026 review concluded that the independent contribution of GIP to long-term cardiovascular protection in people has yet to be established ^[5].

Preliminary Data Signals

No SURMOUNT-MMO outcome results have been published; the trial is event-driven and its estimated primary completion date is October 2027. The closest signals come from other Tirzepatide trials:

• SURPASS-CVOT (type 2 diabetes with atherosclerotic cardiovascular disease): Tirzepatide was non-inferior to the GLP-1 receptor agonist dulaglutide for cardiovascular death, myocardial infarction or stroke (hazard ratio 0.92; superiority was not shown) ^[6]
• SUMMIT (heart failure with preserved ejection fraction and obesity): Tirzepatide lowered the risk of cardiovascular death or worsening heart failure versus placebo (hazard ratio 0.62) ^[7]

Mechanisms Under Investigation

A central open question is whether any cardiovascular benefit is driven primarily by body-weight reduction, direct vascular effects, or metabolic improvements. Areas of mechanistic interest include:

• Cardiac remodelling: Imaging of left ventricular mass; in a cardiac MRI substudy of SUMMIT, Tirzepatide reduced left ventricular mass and paracardiac fat versus placebo, and the change in mass tracked weight loss ^[8]
• Arterial compliance: Pulse wave velocity measurements pre and post treatment
• Inflammatory biomarkers: IL-6, TNF-alpha, and adiponectin trajectory analysis
• Hepatic fat: MRI-PDFF correlations with cardiovascular event rates

Research Peptide Considerations

Academic and independent laboratories studying Tirzepatide's cardiovascular mechanisms require research-grade material meeting specific quality thresholds:

• Purity verification by HPLC: not less than 99%
• Confirmed amino acid sequence by mass spectrometry
• Endotoxin levels below 0.25 EU/mg for vascular cell line studies
• Documented cold-chain handling and storage conditions

The distinction between pharmaceutical-grade Tirzepatide (Mounjaro) and research-grade material is important. Research-grade peptides are synthesised for in vitro and preclinical applications and are not licensed for clinical use.

What Comes Next

Full SURMOUNT-MMO results will show whether Tirzepatide reduces cardiovascular events and deaths in people with obesity without diabetes. Because the comparator is placebo, the trial alone cannot separate the contribution of the GIP component from that of the GLP-1 component ^[1]. If positive, this could reposition dual agonists as the preferred compound class for metabolic and cardiovascular research, displacing single-agonist GLP-1 peptides in many study designs.

References

1. [1] Lam CSP, et al. "Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial." Obesity (Silver Spring). 2025;33(9):1645-1656. PubMed 40545827
2. [2] Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PubMed 37952131
3. [3] Kahles F, et al. "The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE(-/-) mice by blocking monocyte/macrophage activation." Mol Metab. 2018;14:150-157. PubMed 29884547
4. [4] Samms RJ, et al. "GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice." J Clin Invest. 2021;131(12):e146353. PubMed 34003802
5. [5] De Fano M, et al. "GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology." Diabetes Obes Metab. 2026;28(8):6509-6532. PubMed 42209267
6. [6] Nicholls SJ, et al. "Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes." N Engl J Med. 2025;393(24):2409-2420. PubMed 41406444
7. [7] Packer M, et al. "Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity." N Engl J Med. 2025;392(5):427-437. PubMed 39555826
8. [8] Kramer CM, et al. "Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy." J Am Coll Cardiol. 2025;85(7):699-706. PubMed 39566869